SOTIO Enters into Multi-Target Antibody Agreement with Biocytogen to Expand ADC Pipeline
- Option and license agreement includes multiple fully human bispecific antibodies generated with Biocytogen’s proprietary RenLite® platform;
- Agreement will enable SOTIO to significantly broaden its next-generation ADC portfolio, including multi-specific ADCs;
- Biocytogen will receive an upfront payment and potential development milestone payments totaling up to $325.5 million;
SOTIO Announces First Patient Dosed in Phase 1 Clinical Study of SOT201 for Patients with Solid Tumors
- Novel immunocytokine utilizes dual mechanisms of action to activate immune system to fight solid tumors;
- Company has received IND and CTA approval to initiate Phase 1 study in the U.S. and Europe.
SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, today announced the dosing of the first patient in its Phase 1, first-in-human clinical trial evaluating SOT201, a next-generation PD-1-targeting immunocytokine. The VICTORIA-01 study will evaluate the safety, tolerability and initial efficacy of SOT201 monotherapy for the treatment of advanced solid tumors.
SOTIO Presents Overview of DUET-01 Phase 1/2 Study at ASCO Annual Meeting
• Patient enrollment and dosing ongoing in first-in-human study of BOXR1030 enhanced CAR T-cell therapy;
SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, will present on June 1, 2024 (Developmental Therapeutics—Immunotherapy session) a Trial-in-Progress poster on the first-in-human DUET-01 Phase 1/2 study at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The study is evaluating the use of BOXR1030, a metabolically enhanced CAR T-cell therapy, for the treatment of patients with solid tumors.
SOTIO Biotech B.V.
Strawinskylaan 933
1077XX Amsterdam
Netherlands
Strawinskylaan 933
1077XX Amsterdam
Netherlands
SOTIO Biotech a.s.
Českomoravská 2532/19b
190 00 Prague 9
Czech Republic
Českomoravská 2532/19b
190 00 Prague 9
Czech Republic
SOTIO Biotech AG
Lichtstrasse 35 - WSJ-210
4056 Basel
Switzerland
Lichtstrasse 35 - WSJ-210
4056 Basel
Switzerland
SOTIO Biotech Inc.
180 Canal St., Suite 300
Boston, MA 02114
USA
180 Canal St., Suite 300
Boston, MA 02114
USA
Term of use
Data protection
Cookies Policy
Cookie settings
Clinical Trials Privacy Notice
© 2013 - 2024 Sotio
Sitemap
Terms of Use and Privacy
© 2013 - 2024 Sotio